BlackRock Inc
Change company Symbol lookup
Select an option...
BLK BlackRock Inc
PSNL Personalis Inc
PS Pluralsight Inc
POR Portland General Electric Co
PHI PLDT Inc
PD PagerDuty Inc
PBYI Puma Biotechnology Inc
PBF PBF Energy Inc
OGNG Bravo Enterprises Ltd
NNMIF Nearctic Nickel Mines Inc
Go

Financials : Capital Markets | Large Cap Value
Company profile

BlackRock, Inc. (BlackRock) is an investment management company. BlackRock provides a range of investment and risk management services to institutional and retail clients worldwide. Its diverse platform of active (alpha) and index (beta) investment strategies across asset classes enables the Company to tailor investment outcomes and asset allocation solutions for clients. Its product offerings include single- and multi-asset portfolios investing in equities, fixed income, alternatives and money market instruments. Its products are offered directly and through intermediaries in a range of vehicles, including open-end and closed-end mutual funds, iShares exchange-traded funds (ETFs), separate accounts, collective investment funds and other pooled investment vehicles. It offers its Aladdin investment system, as well as risk management, outsourcing, advisory and technology services, to institutional investors and wealth management intermediaries under the BlackRock Solutions name.

Premarket

Last Trade
Delayed
$535.24
-3.30 (-0.61%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$538.54
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
103

10-day average volume:
957,310
103

Moderna's shares rise on vaccine manufacturing deal

7:59 am ET May 1, 2020 (MarketWatch)
Print

Shares of Moderna Inc. (MRNA) gained 2.4% in premarket trading on Friday after the company announced a 10-year manufacturing deal with Lonza Group AG for its COVID-19 vaccine as well as its other vaccine candidates. The companies plan to set up manufacturing facilities in Switzerland, where Lonza is based, and the U.S., where they plan to make the first batch of the investigational vaccine by July. "The current pandemic illustrates the need to combine the best science with resilient supply chains that can scale," Lonza chairman Albert Baehny said in a statement. Moderna has conducted the Phase 1 trial of its COVID-19 vaccine; a Phase 2 study is expected to begin in the second quarter. There are no proven vaccines that prevent infections of the novel coronavirus. Year-to-date, Moderna's stock has soared 135.1%, while shares of Lonza have gained 19.8%. The S&P 500 is down 9.8%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 01, 2020 07:59 ET (11:59 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.